Literature DB >> 21116856

Expression of genes related to apoptosis, cell cycle and signaling pathways are independent of TP53 status in urinary bladder cancer cells.

Glenda N da Silva1, Adriane F Evangelista, Danielle A Magalhães, Cláudia Macedo, Michelle C Búfalo, Elza T Sakamoto-Hojo, Geraldo A S Passos, Daisy M F Salvadori.   

Abstract

Urinary bladder cancer is the fourth most common malignancy in the Western world. Transitional cell carcinoma (TCC) is the most common subtype, accounting for about 90% of all bladder cancers. The TP53 gene plays an essential role in the regulation of the cell cycle and apoptosis and therefore contributes to cellular transformation and malignancy; however, little is known about the differential gene expression patterns in human tumors that present with the wild-type or mutated TP53 gene. Therefore, because gene profiling can provide new insights into the molecular biology of bladder cancer, the present study aimed to compare the molecular profiles of bladder cancer cell lines with different TP53 alleles, including the wild type (RT4) and two mutants (5637, with mutations in codons 280 and 72; and T24, a TP53 allele encoding an in-frame deletion of tyrosine 126). Unsupervised hierarchical clustering and gene networks were constructed based on data generated by cDNA microarrays using mRNA from the three cell lines. Differentially expressed genes related to the cell cycle, cell division, cell death, and cell proliferation were observed in the three cell lines. However, the cDNA microarray data did not cluster cell lines based on their TP53 allele. The gene profiles of the RT4 cells were more similar to those of T24 than to those of the 5637 cells. While the deregulation of both the cell cycle and the apoptotic pathways was particularly related to TCC, these alterations were not associated with the TP53 status.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21116856     DOI: 10.1007/s11033-010-0536-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  43 in total

Review 1.  Design issues for cDNA microarray experiments.

Authors:  Yee Hwa Yang; Terry Speed
Journal:  Nat Rev Genet       Date:  2002-08       Impact factor: 53.242

2.  Cloning and characterization of the human gene DERP6, which activates transcriptional activities of p53.

Authors:  Jian Yuan; Wenwen Tang; Kuntian Luo; Xinya Chen; Xiuting Gu; Bo Wan; Long Yu
Journal:  Mol Biol Rep       Date:  2006-09       Impact factor: 2.316

Review 3.  Analysis and management of microarray gene expression data.

Authors:  Gregory R Grant; Elisabetta Manduchi; Christian J Stoeckert
Journal:  Curr Protoc Mol Biol       Date:  2007-01

Review 4.  p53: traffic cop at the crossroads of DNA repair and recombination.

Authors:  Sagar Sengupta; Curtis C Harris
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

5.  MSSP, a protein binding to an origin of replication in the c-myc gene, interacts with a catalytic subunit of DNA polymerase alpha and stimulates its polymerase activity.

Authors:  T Niki; I Galli; H Ariga; S M Iguchi-Ariga
Journal:  FEBS Lett       Date:  2000-06-23       Impact factor: 4.124

6.  Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

Authors:  Jeremy Kortmansky; Manish A Shah; Andreas Kaubisch; Amanda Weyerbacher; Sandy Yi; William Tong; Rebecca Sowers; Mithat Gonen; Eileen O'reilly; Nancy Kemeny; David I Ilson; Leonard B Saltz; Robert G Maki; David P Kelsen; Gary K Schwartz
Journal:  J Clin Oncol       Date:  2005-02-07       Impact factor: 44.544

7.  Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status.

Authors:  Shiguang Zhao; Jian Zhang; Xu Zhang; Xuesong Dong; Xueying Sun
Journal:  Mol Biol Rep       Date:  2007-05-26       Impact factor: 2.316

8.  Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Authors:  Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Hiroyuki Shibata; Ryunosuke Kanamaru; Chikashi Ishioka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 11.205

9.  Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells.

Authors:  Nobuyuki Hinata; Toshiro Shirakawa; Zhujun Zhang; Akira Matsumoto; Masato Fujisawa; Hiroshi Okada; Sadao Kamidono; Akinobu Gotoh
Journal:  Urol Res       Date:  2003-09-04

10.  Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials.

Authors:  Shi-Jian Ding; Yan Li; Xiao-Xia Shao; Hu Zhou; Rong Zeng; Zhao-You Tang; Qi-Chang Xia
Journal:  Proteomics       Date:  2004-04       Impact factor: 3.984

View more
  11 in total

1.  Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes.

Authors:  Glenda Nicioli da Silva; Elaine Aparecida de Camargo; Daisy Maria Favero Salvadori
Journal:  Mol Biol Rep       Date:  2012-10-09       Impact factor: 2.316

2.  Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.

Authors:  Rosário Pinto-Leite; Isabel Carreira; Joana Melo; Susana Isabel Ferreira; Ilda Ribeiro; Jaqueline Ferreira; Marco Filipe; Carina Bernardo; Regina Arantes-Rodrigues; Paula Oliveira; Lúcio Santos
Journal:  Tumour Biol       Date:  2014-01-24

3.  Genetic Variations in the 3'-untranslated Regions of Genes Involved in the Cell Cycle and Apoptosis Pathways Affect Bladder Cancer Risk.

Authors:  Qiang Zhang; Wenying Wang; Weidong Xu; Mulong Du`; Gaoxiang Ma; Hanting Liu; Haiyan Chu; N A Tong; Meilin Wang; Jianfeng Shao; Zhengdong Zhang; Lin Yuan; Jing Qian
Journal:  Cancer Genomics Proteomics       Date:  2018 Jan-Feb       Impact factor: 4.069

4.  A Prognostic Gene Signature for Hepatocellular Carcinoma.

Authors:  Rong Chen; Meng Zhao; Yanli An; Dongfang Liu; Qiusha Tang; Gaojun Teng
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

5.  The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta-analysis.

Authors:  Yihao Liao; Huiqin Tang; Miaomiao Wang; Keke Wang; Youzhi Wang; Ning Jiang
Journal:  J Clin Lab Anal       Date:  2021-03-29       Impact factor: 2.352

6.  p53 Status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with Bacillus Calmette-Guérin: a meta-analysis.

Authors:  Xiaofeng Zhou; Guan Zhang; Ye Tian
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

7.  Combined detection of the expression of Nm23-H1 and p53 is correlated with survival rates of patients with stage II and III colorectal cancer.

Authors:  Yinying Wu; Yi Li; Xiaoai Zhao; Danfeng Dong; Chunhui Tang; Enxiao Li; Qianqian Geng
Journal:  Oncol Lett       Date:  2016-11-23       Impact factor: 2.967

8.  Association between TP53 gene deletion and protein expression in esophageal squamous cell carcinoma and its prognostic significance.

Authors:  Madiniyet Niyaz; Julaiti Ainiwaer; Abulajiang Abudureheman; Liwei Zhang; Ilyar Sheyhidin; Abduheny Turhong; Ren Cai; Zhichao Hou; Edris Awut
Journal:  Oncol Lett       Date:  2020-06-09       Impact factor: 2.967

9.  Cross-contamination of a UROtsa stock with T24 cells--molecular comparison of different cell lines and stocks.

Authors:  Georg Johnen; Peter Rozynek; Yvonne von der Gathen; Oleksandr Bryk; Ricarda Zdrenka; Christian Johannes; Daniel G Weber; O Brien Igwilo-Okuefuna; Irina Raiko; Jörg Hippler; Thomas Brüning; Elke Dopp
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

10.  p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis.

Authors:  Jun Du; Shu-hua Wang; Qing Yang; Qian-qian Chen; Xin Yao
Journal:  World J Surg Oncol       Date:  2016-04-30       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.